Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fogelman

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Cancer Medicine|June 11, 2020
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinomaJane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 15, 2020
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or olderJonathan D Mizrahi, Jane E Rogers, Kenneth R Hess, et al.
Oncotarget|April 21, 2017
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinomaKrittiya Korphaisarn, Van Karlyle Morris, Michael J Overman, et al.
Pancreas|June 19, 2019
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOXTimothy J Vreeland, Florencia McAllister, Sanaz Javadi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 3, 2018
High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic CancerSarah A Bannon, Maria F Montiel, Jennifer B Goldstein, et al.
British Journal of Cancer|August 14, 2019
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinomaKrittiya Korphaisarn, Van Morris, Jenifer S Davis, et al.
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
Scientific Reports|June 15, 2018
Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung CancerArnab Chattopadhyay, Xinying Yang, Pallavi Mukherjee, et al.
Pancreas|March 14, 2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumabKatherine Van Loon, Anne M Espinoza, David R Fogelman, et al.
Annals of Surgical Oncology|January 20, 2012
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapyChing-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Cancer Medicine|June 11, 2020
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinomaJane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 15, 2020
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or olderJonathan D Mizrahi, Jane E Rogers, Kenneth R Hess, et al.
Oncotarget|April 21, 2017
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinomaKrittiya Korphaisarn, Van Karlyle Morris, Michael J Overman, et al.
Pancreas|June 19, 2019
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOXTimothy J Vreeland, Florencia McAllister, Sanaz Javadi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 3, 2018
High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic CancerSarah A Bannon, Maria F Montiel, Jennifer B Goldstein, et al.
British Journal of Cancer|August 14, 2019
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinomaKrittiya Korphaisarn, Van Morris, Jenifer S Davis, et al.
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
Scientific Reports|June 15, 2018
Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung CancerArnab Chattopadhyay, Xinying Yang, Pallavi Mukherjee, et al.
Pancreas|March 14, 2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumabKatherine Van Loon, Anne M Espinoza, David R Fogelman, et al.
Annals of Surgical Oncology|January 20, 2012
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapyChing-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, et al.
Pageof 6